Data / Research funding / Therapeutic Cannabinoid Research
Therapeutic Cannabinoid Research: 268 NIH awards ($322.6M) to 122 organizations
268 NIH awards ($322.6M) in the NIH spending category Therapeutic Cannabinoid Research, to 122 organizations, read 2026-11-04. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
268 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cannabidiol in the treatment of opioid use disorder | NIH | National Institute on Drug Abuse | 2024 | $10,316,590 | September 30, 2019 | August 31, 2027 | HURD, YASMIN L. | reporter.nih.gov |
| LifeâÂÂs end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial | NIH | National Institute on Aging | 2021 to 2022 | $9,892,823 | September 15, 2020 | April 30, 2026 | MINTZER, JACOBO | reporter.nih.gov |
| Rocky Mountain Cannabis Research Center | NIH | National Institute on Drug Abuse | 2023 to 2025 | $8,380,548 | September 1, 2023 | June 30, 2028 | HUTCHISON, KENT E. | reporter.nih.gov |
| CB1 Neutral Antagonists for Alcohol Use Disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $5,965,782 | September 20, 2020 | August 31, 2025 | MAKRIYANNIS, ALEXANDROS | reporter.nih.gov |
| Translational Studies of Cannabis Administration, Cognition, and the Endocannabinoid System in HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,324,439 | May 1, 2021 | July 31, 2026 | MINASSIAN, ARPI | reporter.nih.gov |
| Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,931,875 | June 1, 2021 | March 31, 2027 | LOGGIA, MARCO LUCIANO | reporter.nih.gov |
| PRODUCTION, ANALYSIS, AND DISTRIBUTION OF CANNABIS AND RELATED MATERIALS. POP: MARCH 23, 2015 - MARCH 22, 2023. N01DA-15-7793. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,928,369 | March 23, 2015 | March 22, 2023 | ELSOHLY, MAHMOUD | reporter.nih.gov |
| Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,584,464 | June 15, 2022 | March 31, 2027 | ELLIS, RONALD J. | reporter.nih.gov |
| Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial (The CORK trial) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $3,579,362 | September 18, 2023 | August 31, 2028 | BRUMMETT, CHAD M | reporter.nih.gov |
| Role of Lifespan Intervention on the Regulation and Progression of Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2024 | $3,503,395 | June 1, 2020 | March 31, 2026 | RIZZO, STACEY J | reporter.nih.gov |
| Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment | NIH | National Cancer Institute | 2023 to 2025 | $3,343,401 | September 19, 2023 | August 31, 2028 | POTOSKY, ARNOLD L | reporter.nih.gov |
| Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,267,557 | September 30, 2020 | June 30, 2026 | MOHAN, MAHESH | reporter.nih.gov |
| Effects of full-spectrum cannabidiol on alcohol consumption and alcohol use disorder phenotypes: implications for precision medicine | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $3,227,517 | September 20, 2025 | August 31, 2029 | KAROLY, HOLLIS C | reporter.nih.gov |
| Peripherally-restricted non-addictive cannabinoids for cancer pain treatment | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $3,174,343 | August 1, 2023 | July 31, 2025 | SPIGELMAN, IGOR | reporter.nih.gov |
| ERP studies of acute influences of THC and CBD on memory encoding and retrieval processes | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,173,683 | August 1, 2021 | May 31, 2027 | CURRAN, TIMOTHY E | reporter.nih.gov |
| Modulation of pain mechanisms by cannabis-derived phytochemicals. | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $3,150,461 | December 1, 2020 | November 30, 2026 | SETO, TODD B | reporter.nih.gov |
| Discriminative Stimulus Effects of Opioid Withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,097,773 | May 1, 1995 | December 31, 2026 | FRANCE, CHARLES P | reporter.nih.gov |
| Analgesic and subjective effects of terpenes administered alone and in combination with THC: Potential THC- and opioid-sparing effects of myrcene and ß-caryophyllene | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $3,089,484 | February 15, 2020 | January 31, 2026 | COOPER, ZIVA D | reporter.nih.gov |
| Cannabis use among older adults: Potential risks and benefits to an aging population | NIH | National Institute on Aging | 2021 to 2025 | $3,055,285 | February 15, 2021 | January 31, 2027 | BRYAN, ANGELA | reporter.nih.gov |
| Development of KLS-13019 for Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $2,970,772 | September 30, 2021 | August 31, 2025 | BRENNEMAN, DOUGLAS ERIC | reporter.nih.gov |
| Mechanism and optimization of CBD-mediated analgesic effects (Diversity Supplement) | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $2,902,023 | September 15, 2019 | June 30, 2025 | HE, ZHIGANG | reporter.nih.gov |
| Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,883,639 | September 30, 2020 | August 31, 2026 | PAPPAS, GEORGE | reporter.nih.gov |
| Cannabinoid interactions with central and peripheral pain mechanisms in osteoarthritis of the knee | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,864,374 | August 1, 2020 | May 31, 2026 | HARTE, STEVEN EDWARD | reporter.nih.gov |
| Opioid and cannabinoid interactions in pain and reward | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,852,096 | September 30, 2020 | June 30, 2026 | NEUBERT, JOHN K | reporter.nih.gov |
| Mechanism of Cannabidiol Effects on HIV Expression, Neuroinflammation, and HIV Cognitive Disease in Chronically-infected Immunocompetent Mice | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,851,386 | September 30, 2020 | July 31, 2025 | VOLSKY, DAVID J | reporter.nih.gov |
| Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study | NIH | National Cancer Institute | 2022 to 2025 | $2,815,567 | April 15, 2022 | March 31, 2027 | MEGHANI, SALIMAH H. | reporter.nih.gov |
| Cannabis Effects on Antiretroviral Therapy, Pharmacokinetics, and Neurotoxicity | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,756,681 | July 1, 2020 | April 30, 2026 | LETENDRE, SCOTT L | reporter.nih.gov |
| Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: A Prospective Cohort Study | NIH | National Institute on Aging | 2022 to 2025 | $2,747,244 | February 15, 2022 | November 30, 2026 | WANG, YAN | reporter.nih.gov |
| Mechanisms of cannabidiol in persons with MS: the role of sleep and pain phenotype | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,725,289 | August 15, 2021 | May 31, 2026 | BRALEY, TIFFANY JOY | reporter.nih.gov |
| Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,671,024 | April 1, 2022 | March 31, 2027 | METRIK, JANE | reporter.nih.gov |
| Drug-gene-nutraceutical interactions of cannabidiol | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,519,234 | February 22, 2022 | January 31, 2027 | EADON, MICHAEL THOMAS | reporter.nih.gov |
| Novel Approaches to Opiate Use Reduction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,469,078 | April 1, 2020 | January 31, 2026 | HUTCHISON, KENT E. | reporter.nih.gov |
| Translating CBD Treatment for Heroin Addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,349,864 | August 1, 2019 | June 30, 2025 | HURD, YASMIN L. | reporter.nih.gov |
| Synaptic transport of endocannabinoids in the brain | NIH | National Institute of Mental Health | 2021 to 2024 | $2,349,284 | April 1, 2021 | February 28, 2026 | HAJ-DAHMANE, SAMIR | reporter.nih.gov |
| Quorum Sensing Regulation of EHEC Virulence Genes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,346,135 | January 1, 2023 | December 31, 2027 | SPERANDIO, VANESSA | reporter.nih.gov |
| Endogenous Cannabinoid Control of Reward Substrates | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,320,372 | March 1, 2008 | April 30, 2027 | CHEER, JOSEPH F | reporter.nih.gov |
| The Impact of Cannabidiol (CBD) Health Claims at Point-of-Sale on Consumer Perceptions and Behavior | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,287,873 | July 15, 2021 | May 31, 2027 | WAGONER, KIMBERLY G. | reporter.nih.gov |
| Peripheral and Central Pathways of α3 Glycine Receptors as Non-Opioid Molecular Targets to Treat Pain | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,282,554 | May 1, 2022 | January 31, 2027 | XU, YAN | reporter.nih.gov |
| Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease | NIH | National Institute on Aging | 2023 | $2,278,287 | April 15, 2023 | March 31, 2026 | CHEN, CHU | reporter.nih.gov |
| Cannabidiol and Macrophage Chronic Inflammation in a Virally Suppressed Rhesus Macaque Model | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,266,058 | September 30, 2020 | June 30, 2025 | WILLIAMS, DIONNA WHITNEY | reporter.nih.gov |
| The Effect of Medical Cannabis Laws on Health Care Use in Insured Populations with Pain | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,228,671 | July 1, 2019 | April 30, 2026 | ABRAHAM, AMANDA J | reporter.nih.gov |
| Treatment of cancer pain by lipid mediator Resolvin D1: role of Prostaglandin and Endocannabinoid signaling | NIH | National Cancer Institute | 2021 to 2025 | $2,219,816 | August 5, 2021 | July 31, 2026 | KHASABOV, SERGEY G | reporter.nih.gov |
| Endocannabinoid Targeting for Opioid Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,190,554 | July 1, 2022 | June 30, 2027 | MILNES, TALLY MARIE | reporter.nih.gov |
| High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,172,679 | May 15, 2022 | February 28, 2027 | OLSON, DAVID E | reporter.nih.gov |
| The Effects of Cannabinoids and Route of Cannabis Administration on Subclinical Cardiovascular Disease Risk | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,169,132 | August 1, 2020 | June 30, 2025 | VIDOT, DENISE CHRISTINA | reporter.nih.gov |
| Endocannabinoids in neurodegenerative diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $2,151,868 | June 15, 2012 | April 30, 2026 | CHEN, CHU | reporter.nih.gov |
| Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial | NIH | National Institute on Aging | 2023 to 2025 | $2,143,253 | July 1, 2023 | June 30, 2028 | HUTCHISON, KENT E. | reporter.nih.gov |
| Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,125,460 | April 15, 2022 | February 28, 2027 | BABALONIS, SHANNA | reporter.nih.gov |
| Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,110,556 | September 30, 2019 | August 31, 2025 | BRIONES, MARISA | reporter.nih.gov |
| Regulation of synaptic plasticity by BDNF-endocannabinoid interactions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,110,192 | December 1, 2019 | November 30, 2026 | LEVINE, ERIC S | reporter.nih.gov |
| Endocannabinoid-Based Treatment for the Neurologic Niemann-Pick Diseases | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,087,153 | September 9, 2022 | August 31, 2027 | SCHUCHMAN, EDWARD H. | reporter.nih.gov |
| Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study | NIH | National Institute on Aging | 2025 | $2,072,617 | August 15, 2025 | July 31, 2028 | MINTZER, JACOBO | reporter.nih.gov |
| SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $2,054,674 | September 1, 2021 | August 31, 2024 | KORMAN, TYLER P | reporter.nih.gov |
| Modulating Signaling Endocannabinoids and Fatty Acid Amides | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,053,125 | December 1, 2021 | November 30, 2026 | BOGER, DALE L | reporter.nih.gov |
| Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $2,051,325 | September 20, 2023 | July 31, 2025 | KIMLESS, DEBRA | reporter.nih.gov |
| Preclinical Assessment of Medications for Alcohol Abuse | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $2,042,668 | September 28, 2007 | March 31, 2025 | WEERTS, ELISE M | reporter.nih.gov |
| Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,031,509 | September 30, 2024 | July 31, 2029 | XU, KE | reporter.nih.gov |
| Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,030,405 | April 20, 2022 | March 31, 2027 | HUTCHISON, KENT E. | reporter.nih.gov |
| A microbial engineering platform for sustainable, scalable, and cost-effective production of pharmaceutical grade cannabinoids and related compounds | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,999,908 | May 16, 2024 | April 30, 2026 | KAMBOURAKIS, SPIROS | reporter.nih.gov |
| Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain | NIH | National Cancer Institute | 2021 to 2022 | $1,979,001 | September 25, 2019 | April 30, 2025 | SCHWIMMER, LAUREN JENNIFER | reporter.nih.gov |
| Allosteric Modulation of the CB1 Receptor | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,940,546 | April 1, 2023 | March 31, 2028 | ZHANG, YANAN | reporter.nih.gov |
| Effect of Cannabis Use on Alcohol Craving and Consumption among those in Alcohol Treatment | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,939,671 | September 15, 2023 | June 30, 2028 | GUNN, RACHEL LYN | reporter.nih.gov |
| Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics | NIH | National Cancer Institute | 2023 to 2025 | $1,930,054 | September 21, 2023 | August 31, 2028 | REBOUSSIN, BETH A. | reporter.nih.gov |
| Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC | NIH | National Cancer Institute | 2023 to 2025 | $1,915,200 | August 1, 2023 | July 31, 2028 | BRYAN, ANGELA | reporter.nih.gov |
| Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study | NIH | National Cancer Institute | 2023 to 2025 | $1,905,214 | September 15, 2023 | August 31, 2028 | ASHARE, REBECCA | reporter.nih.gov |
| Endocannabinoid Metabolism in Acute Pain | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,844,228 | April 15, 2020 | February 28, 2026 | KACZOCHA, MARTIN | reporter.nih.gov |
| Targeting the Endocannabinoid System for Headache Intervention | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,793,296 | January 1, 2023 | December 31, 2027 | MILNES, TALLY MARIE | reporter.nih.gov |
| Mechanisms and treatment of adolescent phytocannabinoid impairment of prefrontal cortex function | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,784,987 | May 1, 2022 | February 28, 2027 | LU, HUI-CHEN | reporter.nih.gov |
| Gene-environment interaction: the brain CRF system in alcohol preferring msP rats | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,774,951 | July 1, 2021 | June 30, 2027 | ROBERTO, MARISA | reporter.nih.gov |
| Cannabidiol and terpenoid interactions in amygdalar regulation of pain states | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $1,717,472 | May 1, 2022 | January 31, 2027 | LAND, BENJAMIN | reporter.nih.gov |
| Enteric glia and visceral pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,715,750 | March 1, 2024 | February 28, 2028 | GULBRANSEN, BRIAN D. | reporter.nih.gov |
| Cannabidiol-enhanced cognitive behavioral therapy for generalized anxiety disorder | NIH | National Institute of Mental Health | 2025 | $1,715,387 | June 1, 2025 | May 31, 2027 | MARUSAK, HILARY | reporter.nih.gov |
| Elucidating the mechanisms of cannabinoids on HIV-1 infection and inflammasome activation | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,704,831 | August 1, 2020 | June 30, 2025 | SWARTZ, TALIA H | reporter.nih.gov |
| Neuro-immune mechanisms of minor cannabinoids in inflammatory and neuropathic pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $1,692,291 | September 15, 2019 | June 30, 2025 | HELLMAN, JUDITH | reporter.nih.gov |
| Exploring the anti-inflammatory properties of cannabis and their relevance to insulin sensitivity | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,652,097 | September 1, 2019 | May 31, 2026 | BRYAN, ANGELA | reporter.nih.gov |
| Circuit and Synaptic Mechanisms of Endocannabinoid-Opioid Crosstalk | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,647,735 | September 30, 2022 | June 30, 2027 | RAJADHYAKSHA, ANJALI M | reporter.nih.gov |
| Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,645,372 | March 1, 2023 | December 31, 2027 | LOGOTHETIS, DIOMEDES E. | reporter.nih.gov |
| Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2022 | $1,628,551 | May 15, 2021 | April 30, 2024 | SINGH, JAGDISH | reporter.nih.gov |
| Development of selective cannabinoid receptor 2 agonists for treatment of addiction | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,621,997 | April 19, 2022 | April 30, 2027 | SHAMLOO, MEHRDAD | reporter.nih.gov |
| Supplement to Basal Forebrain Modulation of Olfactory Bulb Function | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2022 | $1,608,566 | February 1, 2011 | August 31, 2023 | PUCHE, ADAM C | reporter.nih.gov |
| Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $1,560,823 | July 1, 2021 | April 30, 2027 | STREICHER, JOHN MICHAEL | reporter.nih.gov |
| Novel therapeutic approach for NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,553,952 | June 4, 2020 | May 31, 2025 | MAITRA, RANGAN | reporter.nih.gov |
| CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and Dependence | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,551,552 | April 15, 2019 | February 28, 2026 | HOHMANN, ANDREA GRACE | reporter.nih.gov |
| CaV2.2 splice variants in the hippocampus: function and pharmacology | NIH | National Institute of Mental Health | 2022 to 2025 | $1,536,100 | July 1, 2022 | April 30, 2027 | ANDRADE, ARTURO | reporter.nih.gov |
| Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,482,000 | September 30, 2020 | July 31, 2025 | ZHEN, ANJIE | reporter.nih.gov |
| Assessing Benefits and Harms of Medical Cannabis and Cannabinoid Use in Breast Cancer Patients During and After Treatments | NIH | National Cancer Institute | 2023 to 2025 | $1,471,480 | September 20, 2023 | August 31, 2029 | HU, JENNIFER J | reporter.nih.gov |
| Cannabis Use Impact on Pain and Recovery Post-Surgery - The Role of the Endocannabinoid System | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,443,561 | September 5, 2025 | August 31, 2030 | INGRAM, SUSAN L | reporter.nih.gov |
| Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD | NIH | National Institute of Mental Health | 2021 to 2022 | $1,439,782 | February 24, 2017 | May 31, 2025 | RABINAK, CHRISTINE ANNE | reporter.nih.gov |
| Effect of Covid-19 on Caregivers of Persons with Dementia | NIH | National Institute on Aging | 2021 | $1,438,603 | September 1, 2016 | May 31, 2022 | ROSENBERG, PAUL B | reporter.nih.gov |
| Therapeutic Targeting of Monoacylglycerol Lipase After Traumatic Brain Injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,436,743 | August 1, 2020 | April 30, 2026 | VAIBHAV, KUMAR | reporter.nih.gov |
| Biosynthesis and biological mechanism of minor cannabinoids | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,373,136 | December 20, 2023 | October 31, 2028 | MOORE, BRADLEY S | reporter.nih.gov |
| Repeated Administration of Cannabis Varying in THC and CBD: Effects on Abuse Liability, Experimental Pain and Plasma Endocannabinoids | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,341,614 | August 15, 2022 | May 31, 2028 | HANEY, MARGARET | reporter.nih.gov |
| Development of sterol carrier protein 2 inhibitors as anxiolytics | NIH | National Institute of Mental Health | 2024 to 2025 | $1,330,698 | July 1, 2024 | February 29, 2028 | HILLARD, CECILIA J | reporter.nih.gov |
| Health effects of cannabidiol vaping products | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,323,987 | March 1, 2024 | December 31, 2027 | REBULI, MEGHAN ELIZABETH | reporter.nih.gov |
| Cannabis use and the endocannabinoid system in bipolar disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,310,628 | May 1, 2018 | February 29, 2024 | PERRY, WILLIAM | reporter.nih.gov |
| Psychopharmacological effects of cannabidiol on responses to stress and nicotine withdrawal | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,303,839 | September 30, 2010 | February 28, 2029 | AL'ABSI, MUSTAFA | reporter.nih.gov |
| A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,259,835 | July 1, 2020 | June 30, 2025 | WERTH, VICTORIA P | reporter.nih.gov |
| Mechanisms of cannabinoid tolerance | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,242,514 | August 1, 2020 | July 31, 2024 | MORGAN, DANIEL J | reporter.nih.gov |
| Randomized controlled trial of varenicline to treat tobacco and cannabis co-use. | NIH | National Cancer Institute | 2024 to 2025 | $1,201,687 | June 1, 2024 | May 31, 2026 | MCCLURE, ERIN A | reporter.nih.gov |
| A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment | NIH | National Cancer Institute | 2023 to 2024 | $1,194,966 | September 20, 2023 | August 31, 2028 | LEE, RICHARD T | reporter.nih.gov |
| Endocannabinoid Mechanisms in the Pathophysiology of Alcohol Use Disorders | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,189,773 | September 1, 2017 | February 29, 2028 | PATEL, SACHIN | reporter.nih.gov |
| Analgesic efficacy of single and combined minor cannabinoids and terpenes | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $1,188,750 | September 15, 2019 | June 30, 2025 | WARD, SARA J | reporter.nih.gov |
| Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $1,180,991 | September 19, 2022 | February 28, 2026 | SIMON, NAOMI M | reporter.nih.gov |
| Circuit and Synaptic Mechanisms of Endocannabinoid-Opioid Crosstalk | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,157,008 | September 30, 2022 | October 31, 2023 | RAJADHYAKSHA, ANJALI M | reporter.nih.gov |
| REST-mediated regulation of opioid receptors in chronic pain mouse models | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,135,224 | July 1, 2020 | June 30, 2027 | MAJUMDER, SADHAN | reporter.nih.gov |
| Metabolic correlates of disease activity and disability progression in pediatric MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,103,912 | April 1, 2021 | March 31, 2024 | WAUBANT, EMMANUELLE LAURENCE | reporter.nih.gov |
| Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $1,099,216 | January 18, 2022 | April 30, 2025 | TAYLOR, CHARLES | reporter.nih.gov |
| Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 | $1,083,127 | May 15, 2019 | November 30, 2024 | LONDON, EDYTHE DANICK | reporter.nih.gov |
| STATE MEDICAL CANNABIS LAWS, CHRONIC PAIN, AND OPIOIDS: A MIXED-METHODS APPROACH | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,064,118 | July 1, 2020 | April 30, 2025 | MCGINTY, EMMA ELIZABETH | reporter.nih.gov |
| The GPR171 pathway in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,049,334 | April 25, 2023 | March 31, 2028 | ZHU, YUWEN | reporter.nih.gov |
| Endocannabinoid Biosynthesis in Inflammation and Pain | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,034,700 | February 1, 2024 | January 31, 2029 | HSU, KU-LUNG | reporter.nih.gov |
| Anti-inflammatory Effects of Novel Minor Cannabinoids and Terpenes on Cellular and Murine Models of HIV and HIV Proteins | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,034,538 | September 30, 2020 | July 31, 2025 | PARIS, JASON RICHARD | reporter.nih.gov |
| Synthesis of peripherally active CB1 agonists as analgesics | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $1,033,359 | September 29, 2021 | June 30, 2023 | MAJUMDAR, SUSRUTA | reporter.nih.gov |
| FABP5: Novel Functions in Pain Modulation | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $997,694 | March 1, 2024 | February 28, 2029 | KACZOCHA, MARTIN | reporter.nih.gov |
| State Medical Cannabis Laws, Chronic Pain, and Opioids: A Mixed-Methods Approach | NIH | National Institute on Drug Abuse | 2021 to 2022 | $970,075 | July 1, 2020 | September 11, 2022 | MCGINTY, EMMA ELIZABETH | reporter.nih.gov |
| Effects of Early-life Cannabinoid Exposure on Prefrontal Circuitry and Cognitive Behavior across Development | NIH | National Institute on Drug Abuse | 2024 to 2025 | $967,695 | June 1, 2024 | March 31, 2029 | CHE, ALICIA YUE | reporter.nih.gov |
| Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $958,500 | May 1, 2021 | April 30, 2026 | DE AQUINO, JOAO PAULO | reporter.nih.gov |
| AI-Powered Biased Ligand Design | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $954,000 | May 1, 2023 | February 28, 2027 | WANG, JUNMEI | reporter.nih.gov |
| The Effects of Cannabidiol on the Driving Performance of Healthy Adults | NIH | National Institute on Drug Abuse | 2024 to 2025 | $920,550 | September 1, 2024 | May 31, 2029 | RUDISILL, TONI MARIE | reporter.nih.gov |
| Vulnerability and Persistence of Neuroinflammation and Behavioral Deficits from Developmental Cannabinoid Exposure | NIH | National Institute on Drug Abuse | 2024 to 2025 | $885,374 | July 1, 2024 | May 31, 2029 | WILLETT, KRISTINE L | reporter.nih.gov |
| Combination of THC and CBD as a Novel Treatment for Co-Occurring Opioid Addiction and Chronic Pain | NIH | National Institute on Drug Abuse | 2024 to 2025 | $883,050 | May 1, 2024 | February 28, 2028 | DE AQUINO, JOAO PAULO | reporter.nih.gov |
| Chemical biology tools for illuminating cannabinoid signaling pathways in opioid use disorder. | NIH | National Institute on Drug Abuse | 2024 to 2025 | $842,400 | August 15, 2024 | May 31, 2029 | FRANK, JAMES ALLEN | reporter.nih.gov |
| Highs or Lows? Evaluating the Benefits and Consequences of Medical Marijuana Use in Older Adults with Chronic Pain and Opioid Use | NIH | National Institute on Drug Abuse | 2021 to 2022 | $820,000 | September 30, 2019 | July 31, 2024 | GRUBER, STACI A | reporter.nih.gov |
| Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics | NIH | National Center for Complementary & Integrative Health | 2023 to 2024 | $797,291 | September 15, 2019 | June 30, 2026 | GAMAGE, THOMAS F | reporter.nih.gov |
| Pathophysiological mechanisms of cannabidiol in stress regulation | NIH | National Institute of Mental Health | 2025 | $794,696 | May 1, 2025 | February 28, 2030 | BACHI, KEREN | reporter.nih.gov |
| Quantifying effects of comorbidities and genetics on cannabinoid exposure in the elderly | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $794,611 | August 1, 2022 | February 28, 2026 | ZHOU, ZHU | reporter.nih.gov |
| FABPs: Novel Roles in Pain and Inflammation | NIH | National Institute on Drug Abuse | 2021 to 2022 | $790,902 | July 1, 2014 | May 31, 2024 | KACZOCHA, MARTIN | reporter.nih.gov |
| Neuropathic Pain-induced Depression: the Role of mPFC Endocannabinoids | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $779,283 | August 15, 2019 | January 31, 2024 | PAN, BIN | reporter.nih.gov |
| The impact of medical cannabis on pain and inflammation in people living with HIV | NIH | National Institute on Drug Abuse | 2021 to 2024 | $776,700 | July 15, 2021 | February 28, 2026 | SLAWEK, DEEPIKA | reporter.nih.gov |
| Endocannabinoids in Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $774,165 | June 15, 2012 | April 30, 2023 | CHEN, CHU | reporter.nih.gov |
| Endocannabinoid Metabolism and Synaptic Function | NIH | National Institute of Mental Health | 2021 to 2022 | $773,125 | February 5, 2018 | November 30, 2023 | CHEN, CHU | reporter.nih.gov |
| Dronabinol for the reduction of chronic pain and inflammation in people with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $773,104 | June 1, 2022 | May 31, 2027 | CURTIS, SUSANNA | reporter.nih.gov |
| Evaluation of the Smart Talk: Cannabis Awareness and Prevention Curriculum | NIH | National Institute on Drug Abuse | 2025 | $768,528 | June 1, 2025 | February 28, 2030 | HALPERN-FELSHER, BONNIE L | reporter.nih.gov |
| The role of TREM2 in Alzheimer's disease related neuropathogenesis in people with HIV | NIH | National Institute on Aging | 2025 | $768,131 | July 1, 2025 | June 30, 2030 | FIELDS, JEREL ADAM | reporter.nih.gov |
| Antidotes for Acute Cannabinoid Intoxication | NIH | National Institute on Drug Abuse | 2021 to 2022 | $746,997 | September 30, 2018 | July 31, 2024 | MAKRIYANNIS, ALEXANDROS | reporter.nih.gov |
| Role of Macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $746,874 | February 1, 2022 | July 31, 2026 | WILSON, KIESHA | reporter.nih.gov |
| Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $746,308 | August 1, 2019 | August 31, 2023 | CAMILLERI, MICHAEL L. | reporter.nih.gov |
| Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain? | NIH | National Institute on Drug Abuse | 2021 | $733,464 | July 1, 2017 | June 30, 2024 | ARNSTEN, JULIA H. | reporter.nih.gov |
| Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivo | NIH | National Institute on Drug Abuse | 2021 to 2022 | $724,673 | June 1, 2018 | April 30, 2024 | FITTING, SYLVIA | reporter.nih.gov |
| Oral THC consumption during adolescence and its impact on adult mouse brain | NIH | National Institute on Drug Abuse | 2025 | $716,455 | July 1, 2025 | March 31, 2030 | STELLA, NEPHI | reporter.nih.gov |
| Behavioral Pharmacology of Cannabinoid and Terpenoid Effects and Interactions | NIH | National Institute on Drug Abuse | 2021 | $677,123 | September 15, 2017 | April 30, 2024 | VANDREY, RYAN G | reporter.nih.gov |
| Development of non-opioid, non-addictive analgesics for treating neuropathic pain | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $675,107 | March 18, 2025 | January 31, 2030 | THAKUR, GANESH A | reporter.nih.gov |
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $672,377 | September 20, 2025 | August 31, 2030 | WOLINSKY, DAVID | reporter.nih.gov |
| Characterizing the Epidemiology of Cannabidiol (CBD) Use Among US adults | NIH | National Institute on Drug Abuse | 2022 to 2025 | $668,431 | April 1, 2022 | March 31, 2027 | LEAS, ERIC | reporter.nih.gov |
| Biopsychosocial predictors of opioid use for pediatric postsurgical pain | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $666,906 | May 1, 2021 | April 30, 2026 | STONE, AMANDA LEIGH | reporter.nih.gov |
| Development of selective cannabinoid receptor 2 agonists for treatment of addiction | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $661,980 | April 19, 2022 | March 31, 2023 | SHAMLOO, MEHRDAD | reporter.nih.gov |
| Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans | NIH | National Institute on Drug Abuse | 2021 | $657,143 | August 1, 2016 | June 30, 2023 | DUNN, KELLY E | reporter.nih.gov |
| Orexin modulation of brain reward-brain stress system interactions in alcohol withdrawal anxiety | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $654,468 | March 1, 2022 | February 28, 2027 | AVEGNO, ELIZABETH MINOR | reporter.nih.gov |
| An observational study of the effects of edible cannabis and its constituent cannabinoids on pain, inflammation, and cognition | NIH | National Center for Complementary & Integrative Health | 2021 | $654,019 | September 15, 2017 | August 31, 2024 | BIDWELL, L. CINNAMON | reporter.nih.gov |
| Cannabidiol and Macrophage Chronic Inflammation in a Virally Suppressed Rhesus Macaque Model | NIH | National Institute on Drug Abuse | 2024 | $640,462 | July 1, 2024 | June 30, 2026 | WILLIAMS, DIONNA WHITNEY | reporter.nih.gov |
| Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities | NIH | National Institute on Drug Abuse | 2021 to 2022 | $619,214 | August 1, 2018 | June 30, 2024 | MACKIE, KENNETH | reporter.nih.gov |
| Impact of State Cannabis Laws on Cancer Pain Management and Outcomes: A mixed-methods study | NIH | National Cancer Institute | 2024 | $578,284 | August 1, 2024 | February 28, 2025 | CHECK, DEVON | reporter.nih.gov |
| Novel approaches to understanding the role of cannabinoids and inflammation in anxiety | NIH | National Institute on Drug Abuse | 2021 | $562,633 | September 1, 2017 | June 30, 2024 | BIDWELL, L. CINNAMON | reporter.nih.gov |
| Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $560,920 | September 15, 2019 | October 31, 2023 | GAMAGE, THOMAS F | reporter.nih.gov |
| The role of cannabinoid 1 receptor in age-associated diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $551,696 | September 12, 2025 | August 31, 2028 | KIM, YOO | reporter.nih.gov |
| Impact of State Cannabis Laws on Cancer Pain Management and Outcomes: A mixed-methods study | NIH | National Cancer Institute | 2025 | $527,872 | March 1, 2025 | July 31, 2029 | CHECK, DEVON | reporter.nih.gov |
| Discovery of analgesic diterpenoid alkaloids from medicinal Aconitum plants using a metabolomic approach | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $527,283 | April 1, 2023 | March 31, 2027 | KENNELLY, EDWARD JAMES | reporter.nih.gov |
| Multimodal Assessment of Cannabinoid Target Engagement in Adults with Obsessive-Compulsive Disorder | NIH | National Institute of Mental Health | 2021 to 2023 | $513,527 | July 1, 2021 | September 8, 2023 | KAYSER, REILLY REYNS | reporter.nih.gov |
| Mechanisms mediating human enteroendocrine cell differentiation and function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $505,320 | August 1, 2023 | May 31, 2028 | ZEVE, DANIEL RICHARD | reporter.nih.gov |
| The influence of aerobic exercise on consolidation of fear extinction learning in PTSD | NIH | National Institute of Mental Health | 2023 to 2025 | $503,029 | March 3, 2023 | February 29, 2028 | CROMBIE, KEVIN M | reporter.nih.gov |
| Corticolimbic circuitry in adaptive stress coping behavior and subsequent alcohol drinking | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $493,384 | August 15, 2024 | July 31, 2027 | ORNELAS, LAURA C. | reporter.nih.gov |
| Targeting the endocannabinoid signaling in chemical threat agents-induced lung injury | NIH | National Institute of Environmental Health Sciences | 2025 | $489,008 | September 15, 2025 | September 14, 2027 | NAGRE, NAGARAJA | reporter.nih.gov |
| Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways | NIH | National Cancer Institute | 2023 to 2024 | $454,926 | April 1, 2023 | March 31, 2026 | GOLEMIS, ERICA A. | reporter.nih.gov |
| A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy | NIH | National Cancer Institute | 2022 | $452,540 | September 23, 2022 | August 31, 2025 | LEE, RICHARD T | reporter.nih.gov |
| Stemming the opioid-induced pain cascade via cannabinoid modulation | NIH | National Institute on Drug Abuse | 2021 to 2022 | $442,750 | July 1, 2021 | June 30, 2025 | KINSEY, STEVEN G. | reporter.nih.gov |
| The Developmental Effects of Environmental Enrichment on the Minor Cannabinoid Drug Reward and Cannabinoid Receptor Levels | NIH | National Institute on Drug Abuse | 2024 | $440,924 | August 1, 2024 | July 31, 2027 | STAIRS, DUSTIN JEFFREY | reporter.nih.gov |
| Negative allosteric modulation of mu opioid receptors to reverse fentanyl overdose | NIH | National Institute on Drug Abuse | 2024 to 2025 | $435,875 | September 15, 2024 | August 31, 2026 | MACKIE, KENNETH | reporter.nih.gov |
| Kratom and Cannabinoid Constituents: Mechanisms and Interactive Effects in Neuropathic Pain | NIH | National Center for Complementary & Integrative Health | 2023 | $433,710 | August 7, 2023 | July 31, 2025 | WARD, SARA J | reporter.nih.gov |
| Alteration of bronchial epithelium host defenses by marijuana and vaping preparations | NIH | National Institute on Drug Abuse | 2023 to 2024 | $433,125 | September 15, 2023 | August 31, 2025 | CORMET-BOYAKA, ESTELLE A | reporter.nih.gov |
| Cannabinoid-2 receptor signaling in vesicant induced lung injury | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $432,598 | August 18, 2021 | June 30, 2024 | NAGRE, NAGARAJA | reporter.nih.gov |
| Mechanisms of cannabinoid-resistance among oral spirochetes | NIH | National Institute of Dental & Craniofacial Research | 2025 | $431,750 | July 15, 2025 | July 14, 2027 | SCOTT, DAVID A | reporter.nih.gov |
| Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study | NIH | National Cancer Institute | 2025 | $429,162 | August 1, 2025 | July 31, 2027 | VIJAYVERGIA, NAMRATA | reporter.nih.gov |
| Studies of Cannabidiol in Neurodevelopment | NIH | National Institute on Drug Abuse | 2021 to 2022 | $429,000 | April 1, 2021 | March 31, 2024 | HILLARD, CECILIA J | reporter.nih.gov |
| Prenatal exposure to cannabis and child cardiometabolic health outcomes | NIH | National Institute on Drug Abuse | 2024 to 2025 | $429,000 | August 15, 2024 | July 31, 2027 | MOORE, BRIANNA F | reporter.nih.gov |
| Genetically Encoded Optical Biosensors for Dissecting Brain Distribution and Metabolism of Cannabinoids | NIH | National Institute on Drug Abuse | 2021 to 2022 | $427,625 | March 15, 2021 | February 29, 2024 | GU, LIANGCAI | reporter.nih.gov |
| Cannabinoid Effects on Sleep and Pain Mechanisms in Osteoarthritis of the Knee | NIH | National Institute on Drug Abuse | 2021 to 2023 | $427,278 | July 15, 2020 | June 30, 2024 | BOEHNKE, KEVIN FOXMAN | reporter.nih.gov |
| Regulation of Fat Taste by Adiposity and Endocannabinoids: Implications for Obesity | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2024 | $426,361 | December 1, 2022 | November 30, 2025 | BRESLIN, PAUL A. S | reporter.nih.gov |
| Chronic effects of different THC:CBD ratios on executive function and emotional processing in people with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $424,875 | December 1, 2021 | November 30, 2024 | GANDER, PHILLIP EVAN | reporter.nih.gov |
| Mechanism and Therapeutic Potential of CBD to Repair Blood-Brain Barrier Dysfunction in Epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $420,750 | April 1, 2023 | March 31, 2026 | BAUER, BJOERN | reporter.nih.gov |
| Cannabidiol (CBD) as a Potential Therapeutic for Experimental Subarachnoid Hemorrhage | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $420,750 | December 5, 2023 | May 31, 2026 | ROBERTS, JILL MARIE | reporter.nih.gov |
| REST-mediated regulation of opioid receptors in chronic pain mouse models | NIH | National Institute on Drug Abuse | 2021 | $411,960 | July 1, 2020 | June 30, 2024 | MAJUMDER, SADHAN | reporter.nih.gov |
| Cannabidiol as a treatment for alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 | $411,257 | September 1, 2023 | August 31, 2025 | SONG, ZHAO-HUI | reporter.nih.gov |
| Computation-assisted discovery of bioactive minor cannabinoids from hemp | NIH | National Center for Complementary & Integrative Health | 2023 | $408,375 | September 25, 2023 | August 31, 2025 | STEVENS, JAN FREDERIK | reporter.nih.gov |
| Modulation of alpha-7 nicotinic acetylcholine receptor in HIV-infected microglia and brain organoids | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $407,647 | September 1, 2020 | April 30, 2026 | ROSARIO-RODRÍGUEZ, LESTER JOSÉ | reporter.nih.gov |
| Medical Marijuana and chronic musculoskeletal pain in older adults: a multi-level, precision medicine analysis | NIH | National Institute on Aging | 2024 | $405,401 | September 30, 2024 | August 31, 2026 | MARINI, SIMONE | reporter.nih.gov |
| Cannabinoid and opioid modulation of descending pain circuits in chronic pain | NIH | National Institute on Drug Abuse | 2021 | $401,703 | July 1, 2017 | April 30, 2023 | HEINRICHER, MARY MAGDALEN | reporter.nih.gov |
| Inhibition of fatty acid amide hydrolase as a novel strategy to prevent nephrotoxicity of cisplatin. | NIH | National Cancer Institute | 2022 to 2023 | $397,970 | August 16, 2022 | July 31, 2025 | LI, NINGJUN | reporter.nih.gov |
| Endocannabinoid Biosynthesis in Inflammation and Pain | NIH | National Institute on Drug Abuse | 2021 | $397,603 | September 15, 2017 | June 30, 2022 | HSU, KU-LUNG | reporter.nih.gov |
| Allosteric control of monoacylglyceride lipase (MGL) activity | NIH | National Institute on Drug Abuse | 2022 to 2023 | $397,000 | May 1, 2022 | October 31, 2024 | PIOMELLI, DANIELE | reporter.nih.gov |
| Optimization of cannabidiol-based formulations in autism spectrum disorder | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $396,988 | January 1, 2025 | December 31, 2028 | KAPLAN, JOSH | reporter.nih.gov |
| Neurobehavioral effects of cannabidiol in youth alcohol use disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $395,603 | June 1, 2022 | May 31, 2024 | SQUEGLIA, LINDSAY | reporter.nih.gov |
| Effects of cannabis use on community-based alcohol treatment outcomes in adolescents | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $394,524 | September 20, 2024 | August 31, 2029 | WYCOFF, ANDREA M. | reporter.nih.gov |
| The therapeutic effect of cannabigerol (CBG) with or without cannabidiol (CBD) in diet-induced non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $377,986 | August 1, 2024 | July 31, 2027 | HAN, YUYAN | reporter.nih.gov |
| Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD). | NIH | National Institute on Drug Abuse | 2023 to 2025 | $375,000 | June 1, 2023 | August 31, 2025 | ALAPAFUJA, SHAKIRU OLAJIRE | reporter.nih.gov |
| Traumatic stress increases alcohol drinking via endocannabinoid disinhibition of basolateral amygdala | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $369,493 | September 15, 2017 | July 31, 2024 | GILPIN, NICHOLAS WARREN | reporter.nih.gov |
| THERAPY FOR ALCOHOL USE DISORDER | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 | $368,673 | September 25, 2023 | August 31, 2025 | SELTZMAN, HERBERT H | reporter.nih.gov |
| From the Scanner to the Clinic: Patient Oriented Research and Mentorship | NIH | National Institute on Drug Abuse | 2021 to 2023 | $363,456 | August 15, 2020 | July 31, 2026 | MARTINEZ, DIANA M | reporter.nih.gov |
| Injury-Induced Pain: Chemical Modulation of Nociceptors | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $358,203 | April 1, 1989 | November 30, 2023 | RAJA, SRINIVASA N. | reporter.nih.gov |
| Developing multitarget enzyme inhibitors as safe and effective anti-migraine treatments | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $357,093 | August 1, 2023 | June 30, 2027 | KANDASAMY, RAM | reporter.nih.gov |
| The Role of Endocannabinoids in Adulthood Alcohol Drinking After Adolescent Social Isolation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $352,296 | July 15, 2023 | September 30, 2024 | VOZELLA, VALENTINA | reporter.nih.gov |
| Cannabinoid control of epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $350,775 | July 1, 2017 | March 31, 2023 | SOLTESZ, IVAN | reporter.nih.gov |
| Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain | NIH | National Cancer Institute | 2021 | $337,106 | March 1, 2010 | February 28, 2023 | VANDERAH, TODD W | reporter.nih.gov |
| Combination Therapeutic for Chronic Opioid Use Disorder Relapse | NIH | National Institute on Drug Abuse | 2023 | $335,700 | July 1, 2023 | June 30, 2025 | CASTOR, TREVOR P. | reporter.nih.gov |
| Pseudocannabinoids for mitigation of substance use disorder | NIH | National Institute on Drug Abuse | 2025 | $334,343 | June 15, 2025 | May 31, 2027 | MASCAL, MARK | reporter.nih.gov |
| Role of CB1 Receptors in Opioid Tolerance During Pain | NIH | National Institute on Drug Abuse | 2021 to 2022 | $333,000 | September 30, 2019 | August 31, 2023 | WILSON-POE, ADRIANNE RAE | reporter.nih.gov |
| Impact of cannabidiol on HIV infection and methamphetamine abuse associated neuroinflammation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $307,000 | April 1, 2024 | March 31, 2027 | CHAND, SUBHASH | reporter.nih.gov |
| A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometry | NIH | National Institute of General Medical Sciences | 2025 | $306,872 | August 1, 2025 | July 31, 2026 | PRINCE, ROBIN | reporter.nih.gov |
| Neurocognitive implications of cannabidiol (CBD) while aging with HIV | NIH | National Institute on Drug Abuse | 2022 to 2023 | $295,000 | July 1, 2022 | June 30, 2025 | RODRIGUEZ, MYOSOTYS | reporter.nih.gov |
| Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $293,749 | June 1, 2023 | May 31, 2025 | DRAGANSKI, ANDREW R | reporter.nih.gov |
| Antibody agonist for a G protein-coupled receptor as a treatment for pain in endometriosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $292,942 | June 10, 2022 | May 31, 2024 | TAKEUCHI, TOSHIHIKO | reporter.nih.gov |
| Endocannabinoid Mechanisms in the Pathophysiology of Alcohol Use Disorders | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $289,707 | September 1, 2017 | January 1, 2022 | PATEL, SACHIN | reporter.nih.gov |
| Development of dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors as a Promising Therapeutic Strategy for the Treatment of Acute and Chronic Pain | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $284,000 | May 1, 2020 | April 30, 2023 | PECIC, STEVAN | reporter.nih.gov |
| Investigating the therapeutic potential of CB2 in modulation of inflammation in the mammary gland during lactation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $282,665 | September 1, 2022 | July 31, 2025 | PEREZ LASPIUR, JULIANA | reporter.nih.gov |
| Planning Grant for a Clinical Trial Of Cannabidiol For Postoperative Opioid Reduction in Primary Total Knee Arthroplasty | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $274,560 | August 2, 2021 | July 31, 2023 | BOEHNKE, KEVIN FOXMAN | reporter.nih.gov |
| Understanding cannabidiol policy and its impacts on broader substance use | NIH | National Institute on Drug Abuse | 2025 | $268,470 | April 15, 2025 | September 1, 2025 | POWELL, DAVID | reporter.nih.gov |
| Patient Oriented Research and Mentoring in Multidisciplinary Chronic Pain Treatments | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $255,917 | September 6, 2024 | August 31, 2029 | KRATZ, ANNA LOUISE | reporter.nih.gov |
| Neural circuit control of mesolimbic dopamine and reward | NIH | National Institute on Drug Abuse | 2021 | $249,000 | September 1, 2020 | August 31, 2023 | COVEY, DANIEL PATRICK | reporter.nih.gov |
| Neural circuit control of mesolimbic dopamine and reward | NIH | National Institute on Drug Abuse | 2022 | $245,741 | September 1, 2020 | August 31, 2023 | COVEY, DANIEL PATRICK | reporter.nih.gov |
| Real Time Monitoring of Prescription Opioid and Cannabis Co-Use in Patients with Chronic Pain | NIH | National Institute on Drug Abuse | 2021 | $245,625 | March 15, 2020 | February 28, 2023 | THRUL, JOHANNES | reporter.nih.gov |
| Nutrition-based interventions to ameliorate pain in sickle cell disease | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $241,268 | April 1, 2024 | March 31, 2026 | ARGUETA, DONOVAN ALEXANDER | reporter.nih.gov |
| Beta-caryophyllene (BCP) and cannabidiol (CBD) combination: HIV-1 chronic neuropathic pain | NIH | National Institute on Drug Abuse | 2021 to 2022 | $241,100 | September 30, 2021 | April 30, 2023 | BENAMAR, KHALID | reporter.nih.gov |
| Effect on CBD on Exosome release from CNS infected cells | NIH | National Institute on Drug Abuse | 2021 | $236,054 | May 1, 2020 | October 31, 2023 | KASHANCHI, FATAH | reporter.nih.gov |
| Circuit Modulation in Spinocerebellar Ataxias: Mechanisms and Impact | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $233,280 | December 1, 2024 | November 30, 2029 | SRINIVASAN, SHARAN RAM | reporter.nih.gov |
| Impact on adult mouse brain of oral THC and CBD consumption during adolescence | NIH | National Institute on Drug Abuse | 2021 | $233,250 | July 15, 2020 | June 30, 2023 | STELLA, NEPHI | reporter.nih.gov |
| Functional efficacy of cannabidiol in modulating the adverse effects of heroin in primates. | NIH | National Institute on Drug Abuse | 2024 | $232,500 | August 1, 2024 | July 31, 2026 | KO, MEI-CHUAN | reporter.nih.gov |
| Inhibition of diacylglycerol lipase α as a novel strategy to mitigate the nephrotoxicity of cisplatin | NIH | National Cancer Institute | 2025 | $227,221 | January 1, 2025 | December 31, 2026 | LI, NINGJUN | reporter.nih.gov |
| Chemoenzymatic synthesis and pharmacological evaluation of designer plant meroterpenoids | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $221,404 | April 1, 2023 | March 31, 2026 | LOVE, ANNA CLAIRE | reporter.nih.gov |
| Corticolimbic circuitry in adaptive stress coping behavior and subsequent alcohol drinking | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $204,658 | August 1, 2022 | July 31, 2024 | ORNELAS, LAURA C. | reporter.nih.gov |
| Effects of Repeated Cannabis Administration on Experimental Pain and Abuse Liability in Humans | NIH | National Institute on Drug Abuse | 2021 | $198,875 | September 30, 2020 | August 31, 2024 | AROUT, CAROLINE A | reporter.nih.gov |
| The Ability of the Inhaled Dronabinol to Reduce the Severity of Naloxone-Precipitated Withdrawal | NIH | National Institute on Drug Abuse | 2022 | $198,875 | September 30, 2020 | August 31, 2023 | JONES, JERMAINE D | reporter.nih.gov |
| Pilot Trial of CBD for Sleep in People with HIV | NIH | National Institute on Drug Abuse | 2021 | $197,500 | September 30, 2020 | August 31, 2023 | CHERNER, MARIANA | reporter.nih.gov |
| Development of Tetrahydrocannabivarin as a Treatment for Smokers | NIH | National Institute on Drug Abuse | 2024 | $196,875 | August 15, 2024 | July 31, 2026 | RAY, LARA A. | reporter.nih.gov |
| TRPV1 signaling as a sex-specific mechanism of contextual fear generalization | NIH | National Institute of Mental Health | 2021 | $196,250 | February 1, 2020 | December 31, 2023 | SHANSKY, REBECCA M | reporter.nih.gov |
| Cannabinoid Receptor Type 2 Agonist as Potential Therapy for Neuroinflammation in HIV-1 Associated Neurocognitive Disorders | NIH | National Institute on Drug Abuse | 2024 | $194,940 | January 1, 2024 | December 31, 2024 | MIN, ALICE KYUNGSUN | reporter.nih.gov |
| Dronabinol for the reduction of chronic pain and inflammation in people with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $194,184 | September 1, 2021 | May 31, 2022 | CURTIS, SUSANNA | reporter.nih.gov |
| Cannabidiol (CBD)-only use in Pregnancy and Perinatal Outcomes | NIH | National Institute on Drug Abuse | 2025 | $188,482 | February 1, 2025 | January 31, 2030 | BHATIA, DEVIKA | reporter.nih.gov |
| Effects of Repeated CBD Administration on Cannabis Abuse-Liability and Analgesia: A Human Laboratory Study | NIH | National Institute on Drug Abuse | 2024 | $180,360 | August 1, 2024 | July 31, 2029 | HARRIS, HANNAH MARIE | reporter.nih.gov |
| Effects of Repeated CBD Administration on Cannabis Abuse-Liability and Analgesia: A Human Laboratory Study | NIH | National Institute on Drug Abuse | 2025 | $179,762 | August 11, 2025 | July 31, 2029 | HARRIS, HANNAH MARIE | reporter.nih.gov |
| FAAH-regulated endocannabinoid signaling controls nociception in acute pancreatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $169,388 | September 9, 2025 | July 31, 2030 | MABOU TAGNE, ALEX | reporter.nih.gov |
| Identifying Treatment Effects, Mechanisms, and Moderators in Youth Cannabis Use Treatment Using Ecological Momentary Assessment | NIH | National Institute on Drug Abuse | 2021 to 2023 | $167,844 | September 27, 2021 | December 31, 2023 | PARNES, JAMIE | reporter.nih.gov |
| Measuring effects of morphine withdrawal on dopaminergic salience coding across the striatum | NIH | National Institute on Drug Abuse | 2023 to 2024 | $167,589 | July 1, 2021 | March 31, 2025 | GOMEZ, DEVAN MARC | reporter.nih.gov |
| Role of macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $162,501 | February 1, 2022 | August 7, 2023 | WILSON, KIESHA | reporter.nih.gov |
| Shared mechanisms of alcohol use disorder and Anxiety and effects of the endocannabinoid system | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $124,883 | August 1, 2021 | July 31, 2024 | MARTIN-WILLETT, RENEE | reporter.nih.gov |
| Evaluation of peripheral cannabinoid receptors as a target for pain management | NIH | National Institute on Drug Abuse | 2021 to 2022 | $121,722 | April 1, 2020 | December 31, 2022 | SLIVICKI, RICHARD | reporter.nih.gov |
| The Genetics of Cannabinoid Signaling: An Organismal Analysis | NIH | National Institute of General Medical Sciences | 2025 | $112,000 | September 1, 2025 | August 31, 2029 | LEAL, SANDRA MARIE | reporter.nih.gov |
| Inflammatory injury-mediated synaptic plasticity in the periaqueductal gray | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $110,407 | September 30, 2021 | March 31, 2023 | BREWER, CHELSIE L | reporter.nih.gov |
| Investigating the role of THC in mediating pain signaling in the BLA | NIH | National Institute on Drug Abuse | 2024 to 2025 | $91,934 | August 1, 2024 | July 31, 2027 | ELLIOFF, KAYLIN | reporter.nih.gov |
| Modulation of pain hypersensitivity by terpenes via endocannabinoid release in descending circuits | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $89,906 | July 1, 2024 | June 30, 2026 | RICE, MYRA JANE | reporter.nih.gov |
| Effects of GABA Co-Release on Alcohol-Induced Synaptic Plasticity | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $87,223 | September 1, 2020 | December 9, 2022 | BLOODGOOD, DANIEL W | reporter.nih.gov |
| Structural investigation of a type III polyketide synthase involved in cannabinoid biosynthesis | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $84,073 | June 30, 2022 | June 29, 2024 | GONZALEZ-DEWHITT, KRISTOFER R. | reporter.nih.gov |
| Alcohol-Cannabinoid System Interactions in the Context of Pain and AUD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $82,218 | August 1, 2024 | July 31, 2028 | LEE, STEPHANIE SUMIN | reporter.nih.gov |
| Cannabidiol and buprenorphine: A poly-pharmacy approach to treat opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $78,052 | May 1, 2025 | August 30, 2026 | GALBO THOMMA, LINDSEY | reporter.nih.gov |
| Drug-drug interactions between cannabis and hydrocodone. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $77,985 | August 16, 2022 | August 17, 2024 | COATES, SHELBY | reporter.nih.gov |
| Regulation of Pain by Alcohol and Endocannabinoids in the Basolateral Amygdala | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $73,262 | August 20, 2020 | May 31, 2023 | CUCINELLO-RAGLAND, JESSICA | reporter.nih.gov |
| The role of Cannabinoid Receptor 2 in cerebrovascular protection following traumatic brain injury | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $71,254 | February 1, 2023 | December 31, 2025 | BULLOCK, TRENT A | reporter.nih.gov |
| Somatosensory corticospinal neurons as a biomarker for mind-body pain management strategies | NIH | National Center for Complementary & Integrative Health | 2021 | $70,458 | September 1, 2020 | August 31, 2022 | PAGE, JESSICA | reporter.nih.gov |
| Brain temperature and tissue microstructure in treatment-resistant epilepsy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $58,059 | June 23, 2022 | August 31, 2023 | SHARMA, AYUSHE ALICIA | reporter.nih.gov |
| Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) | NIH | National Center for Complementary & Integrative Health | 2023 | $51,979 | September 27, 2019 | December 31, 2024 | RADHAKRISHNAN, RAJIV | reporter.nih.gov |
| Endocannabinoid Modulation of the HIV-Induced Microglial Inflammatory Response | NIH | National Institute on Drug Abuse | 2024 | $48,974 | June 17, 2024 | June 16, 2025 | ELLISON, ALYSHA | reporter.nih.gov |
| The Ionotropic Cannabinoid Receptor TRPV1 | NIH | National Institute on Drug Abuse | 2021 to 2022 | $44,079 | July 1, 2021 | August 9, 2022 | MULLER, CHANTÉ | reporter.nih.gov |
| Assessing Targeted Cannabinoid Therapeutic Potential Against HIV-1 Associated Neuronal Hyperexcitability and Neuroinflammation | NIH | National Institute on Drug Abuse | 2022 | $37,842 | May 15, 2022 | May 14, 2023 | LEAGUE, ALEXIS | reporter.nih.gov |
| The Role of Amygdalar Endocannabinoids in Alcohol Drinking after Traumatic Brain Injury (TBI) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $36,030 | July 1, 2018 | May 19, 2022 | STIELPER, ZACHARY | reporter.nih.gov |
| The influence of aerobic exercise on consolidation of fear extinction learning in PTSD | NIH | National Institute of Mental Health | 2023 | $35,929 | March 3, 2023 | August 15, 2023 | CROMBIE, KEVIN M | reporter.nih.gov |
| Investigating the Human Metabolism of the Minor Cannabinoid Cannabichromene | NIH | National Center for Complementary & Integrative Health | 2025 | $35,082 | February 1, 2025 | January 31, 2028 | WARD, ALEXANDRA | reporter.nih.gov |
| Mechanisms and treatment of pain-depressed behavior | NIH | National Institute on Drug Abuse | 2021 | $31,366 | August 25, 2020 | May 2, 2022 | DIESTER, CLARE | reporter.nih.gov |
| Cannabinoid type 2 receptors as a therapeutic target for substance use disorders | NIH | National Institute on Drug Abuse | 2023 | $8,368 | February 1, 2023 | February 20, 2023 | CAREY IV, LAWRENCE MICHAEL | reporter.nih.gov |
| Role of CB2R Modulation in HIV-Induced Cathepsin B Neurotoxicity | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $8,308 | September 1, 2020 | November 30, 2021 | ROSARIO-RODRÍGUEZ, LESTER JOSÉ | reporter.nih.gov |
| Target Engagement and Clinical Symptom Change with a FAAH Inhibitor for Posttraumatic Stress Disorder | NIH | National Institute of Mental Health | 2022 | $1 | September 5, 2022 | December 14, 2022 | STEIN, MURRAY B. | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 114 | $60,798,598 | 0 | $0 |
| 2024 | 121 | $67,934,413 | 0 | $0 |
| 2023 | 134 | $69,259,582 | 0 | $0 |
| 2022 | 129 | $64,686,865 | 0 | $0 |
| 2021 | 114 | $59,894,626 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.